1. Home
  2. QDEL vs CDNA Comparison

QDEL vs CDNA Comparison

Compare QDEL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$11.06

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.65

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
CDNA
Founded
1979
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2022
2007

Fundamental Metrics

Financial Performance
Metric
QDEL
CDNA
Price
$11.06
$20.65
Analyst Decision
Hold
Buy
Analyst Count
4
6
Target Price
$28.25
$28.00
AVG Volume (30 Days)
3.0M
742.5K
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
0.05
Revenue
$2,730,200,000.00
$48,324,000.00
Revenue This Year
$3.51
$16.01
Revenue Next Year
$3.86
$11.31
P/E Ratio
N/A
$428.60
Revenue Growth
N/A
18.93
52 Week Low
$9.92
$10.96
52 Week High
$35.58
$23.24

Technical Indicators

Market Signals
Indicator
QDEL
CDNA
Relative Strength Index (RSI) 39.66 52.61
Support Level $10.86 $16.63
Resistance Level $12.85 $21.20
Average True Range (ATR) 0.90 1.41
MACD 0.12 -0.10
Stochastic Oscillator 40.78 51.65

Price Performance

Historical Comparison
QDEL
CDNA

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: